1-4 of 4
Mark R. Bray
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma

Horace H.Y. Lee, Kin Long Chow, Ho Shing Wong, Tsz Yan Chong, Alice S.T. Wong, Grace H.W. Cheng, Jasmine M.K. Ko, Hoi Cheong Siu, Maximus C.F. Yeung, Michael S.Y. Huen, Ka Yu Tse, Mark R. Bray, Tak Wah Mak, Suet Yi Leung, Philip P.C. Ip
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3904–3918.
https://doi.org/10.1158/1078-0432.CCR-23-3720
Published: 03 September 2024
View article titled, Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma
Open the PDF for Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair–Deficient Uterine Leiomyosarcoma in another window
Includes: Supplementary data
Journal Articles

Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models

Jennifer R. Diamond, S. Gail Eckhardt, Aik Choon Tan, Timothy P. Newton, Heather M. Selby, Kelsey L. Brunkow, Maria I. Kachaeva, Marileila Varella-Garcia, Todd M. Pitts, Mark R. Bray, Graham C. Fletcher, John J. Tentler
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 291–303.
https://doi.org/10.1158/1078-0432.CCR-12-1611
Published: 02 January 2013
View article titled, Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
Open the PDF for Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models in another window
Includes: Supplementary data
Journal Articles

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

Jennifer R. Diamond, Bruno R. Bastos, Ryan J. Hansen, Daniel L. Gustafson, S. Gail Eckhardt, Eunice L. Kwak, Shuchi S. Pandya, Graham C. Fletcher, Todd M. Pitts, Gillian N. Kulikowski, Mark Morrow, Jamie Arnott, Mark R. Bray, Carolyn Sidor, Wells Messersmith, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 849–860.
https://doi.org/10.1158/1078-0432.CCR-10-2144
Published: 15 February 2011
View article titled, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors
Open the PDF for Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models

John J. Tentler, Erica L. Bradshaw-Pierce, Natalie J. Serkova, Kendra M. Hasebroock, Todd M. Pitts, Jennifer R. Diamond, Graham C. Fletcher, Mark R. Bray, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (11): 2989–2998.
https://doi.org/10.1158/1078-0432.CCR-10-0325
Published: 31 May 2010
View article titled, Assessment of the <em>In vivo</em> Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models
Open the PDF for Assessment of the <em>In vivo</em> Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models in another window